Arch Therapeutics Inc Stock News

Here is how Arch Therapeutics, Inc. (ARTH) and Amphastar Pharmaceuticals (AMPH) have performed compared to their sector so far this year.

Here is how Arch Therapeutics, Inc. (ARTH) and Haemonetics (HAE) have performed compared to their sector so far this year.

Here is how Arch Therapeutics, Inc. (ARTH) and Cardinal Health (CAH) have performed compared to their sector so far this year.

FRAMINGHAM, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, tod

SAWC Spring 2023 represents first clinical conference opportunity to introduce newly effective dedicated AC5 HCPCS reimbursement code SAWC Spring 2023 represents first clinical conference opportunity

Prestigious Honor Supports Increasing Interest in Broad Clinical Benefits of Synthetic Products in Wound Healing Prestigious Honor Supports Increasing Interest in Broad Clinical Benefits of Synthetic

FRAMINGHAM, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH ) (" Arch " or the " Company "), a marketer and developer of novel self-assembling wound care and biosurgical devices, today announced a study of its proprietary adaptive self-assembling barrier scaffold (aSABS) and peptide technology, AC5 ® Advanced Wound System, demonstrated marked clinical benefit in patients with significant comorbidities and nonhealing wounds. The results of the study were published in the January 2022 issue of the peer-reviewed WOUNDS journal. The manuscript is currently available online here and is expected to be available in physical form later this month. Clinical insights gathered from the study concluded that the use of aSABS: had a marked effect on wound healing by interrupting the stalled inflammatory phase, reducing the bioburden of infected wound tissue, and stimulating the progression of the wound through the proper biological sequence of repair contributed to fast-paced healing (3 weeks in some cases)with only weekly clinic visits and reapplication resulted in the healing of wounds that have been persistently inflamed and infected and for which other advanced wound products and surgical debridement had been unsuccessfuleven in patients with considerable systemic comorbidities may offer clinicians an alternative to high-acuity operating rooms by facilitating debridement and management of some complex wounds in low-acuity outpatient clinic settings improved patients'' quality of life and the at-home burden of wound care for both patients and their caretakers may provide a favorable effect on patient morbidity and mortality in wound management may reduce burden on the health care system Together, the new study along with data presented by multiple

Significantly Expands Access to Include All Federal Government Agencies Significantly Expands Access to Include All Federal Government Agencies

Renowned Expert Dr. Christopher Gauland Shares Insights on Treating DFUs and Success with AC5 ® Advanced Wound System

Arch Therapeutics, Inc. (OTCMKTS:ARTH) was the target of a large decline in short interest in November. As of November 15th, there was short interest totalling 200 shares, a decline of 99.6% from the October 31st total of 51,100 shares. Based on an average daily trading volume, of 299,400 shares, the days-to-cover ratio is currently 0.0 []

Arch Therapeutics (OTCMKTS:ARTH) and Nephros (NASDAQ:NEPH) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership. Institutional & Insider Ownership 0.0% of Arch Therapeutics shares are held by institutional investors. Comparatively, 58.0% []

Nephros (NASDAQ:NEPH) and Arch Therapeutics (OTCMKTS:ARTH) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, earnings, dividends and institutional ownership. Analyst Recommendations This is a breakdown of recent ratings and recommmendations for Nephros and Arch Therapeutics, []

AC5® Advanced Wound System Selected for Innovation Spotlight AC5® Advanced Wound System Selected for Innovation Spotlight

Key Opinion Leaders Share Insights on Advancing Wound Care Key Opinion Leaders Share Insights on Advancing Wound Care

90-Day Report Card for Commercialization Effort